- Home
- BNTX vs VTR Comparison
BNTX vs VTR Comparison
Compare BNTX & VTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | VTR |
|---|---|---|
| Founded | 2008 | 1983 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 36.3B |
| IPO Year | 2019 | 1998 |
Fundamental Metrics
Financial Performance| Metric | BNTX | VTR |
|---|---|---|
| Price | $95.02 | $77.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $137.40 | $78.43 |
| AVG Volume (30 Days) | 1.4M | ★ 3.1M |
| Earning Date | 11-03-2025 | 02-11-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | $3,698,814,972.00 | ★ $5,544,046,000.00 |
| Revenue This Year | $2.03 | $17.34 |
| Revenue Next Year | N/A | $10.07 |
| P/E Ratio | ★ N/A | $146.68 |
| Revenue Growth | 3.70 | ★ 16.38 |
| 52 Week Low | $81.20 | $56.68 |
| 52 Week High | $129.27 | $81.89 |
Technical Indicators
Market Signals| Indicator | BNTX | VTR |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 42.15 |
| Support Level | $94.00 | $78.66 |
| Resistance Level | $95.71 | $80.02 |
| Average True Range (ATR) | 1.74 | 1.16 |
| MACD | 0.52 | -0.30 |
| Stochastic Oscillator | 62.66 | 27.21 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About VTR Ventas Inc.
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.